News and Announcements
Collaborate Corporation’s DriveMyCar Expands Subaru Deal with 105 Additional Vehicles
- Published June 23, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Collaborate Corporation Limited (ASX:CL8) has announced that DriveMyCar business unit has expanded its successful relationship with Subaru Australia. Following a highly successful collaboration in March 2017 around the launch of the Subaru Impreza, Subaru will now provide 105 of the new 2018 model Subaru XV for rental through DriveMyCar in September 2017.
KEY TAKEAWAYS:
- 105 Subaru XV 2018 model vehicles to be added to the DriveMyCar fleet
- Follows successful campaign featuring 101 Subaru Impreza vehicles launched in March 2017
- Subaru and DriveMyCar continue collaboration on unique experiential marketing campaigns
- Largest ever addition of vehicles to the DriveMyCar fleet
- Material contribution to revenue and gross profit growth expected.
Subaru Australia Managing Director, Colin Christie described the Impreza campaign, which saw over 20,000 people experience driving or riding in the new Impreza as ‘astonishingly successful’.
Following that success Subaru will use the same experiential marketing technique for the launch of the new 2018 Subaru XV.
Subaru Australia Managing Director, Colin Christie, said: “Our previous success with the Levorg and Impreza models gives us every confidence that we can continue to expand our audience through use of the new XV, in collaboration with DriveMyCar.
“It’s another great example of our Subaru ‘do’ customer-centric philosophy of continually finding new ways to engage with both existing and prospective customers.”
Chris Noone, Collaborate Corporation CEO said “Our relationship with Subaru is going from strength to strength and this new deal is further evidence of how our online marketplaces can deliver unique benefits to consumers and marketers. We received very positive feedback from renters about the Impreza vehicles, including enquiries about purchasing. We anticipate the XV will be just as popular.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
